MEDIVIR, INTERIM REPORT, 1 January - 31 March 2005

•In March, Boehringer Ingelheim (BI) concluded its research collaboration with Medivir on the HIV compound MIV-310. Medivir has decided to prioritize its protease projects, and accordingly, this project becomes dormant until further notice. •Consolidated net sales were SEK 13.7 (4.9) m in the period. •The loss after tax was SEK -36.2 (-45.4) m; earnings per share were SEK -2.81 (-5.28). FOR MORE INFORMATION, PLEASE CONTACT Rein Piir, CFO and VP, Investor Relations: +46 (0)70 853 7292. FORTHCOMING FINANCIAL INFORMATION The Annual General Meeting will be held on today’s date, at the Polstjärnan Conference Facility, Sveavägen 77, Stockholm, Sweden, from 3 p.m. The Six-month Interim Report will be published on 7 July 2005. The Nine-month Interim Report will be published on 26 October 2005. Medivir’s financial reports are available from its Website, www.medivir.se from these dates, under the ‘Financial Information’ heading.